Noppachai Siranart

With recurrent weight gain after sleeve gastrectomy, the choice between endoscopic repair and another operation can change both safety and recovery planning. Noppachai Siranart has contributed to research comparing endoscopic sleeve-in-sleeve repair with surgical revision in a matched cohort of 164 patients, reporting similar weight-loss outcomes at 6 and 12 months while serious adverse events were 0% with endoscopic repair versus 11% with surgical revision. At YOUNIFY Clinic, he works as a specialist in Gastroenterology, with expertise in advanced endoscopy and obesity and metabolic disease management.

His clinical and educational materials also address how GLP-1 receptor agonists may affect gastric emptying and upper endoscopy workflow. In patient-friendly summaries, he emphasizes that decisions about continuing or pausing GLP-1 before gastroscopy should consider symptoms, diabetes status, medication timing, and procedure risk rather than a one-size-fits-all rule. He specifically discusses commonly used agents such as semaglutide, liraglutide, dulaglutide, and tirzepatide, and the importance of sharing the exact drug name, dose, and last dose date with the endoscopy team.

For metabolic liver disease, Siranart has been involved in a meta-analysis on GLP-1 receptor agonists and biopsy-confirmed MASH, a form of fatty liver disease characterized by inflammation and liver cell injury. The goal in this area is to support safer weight management while coordinating long-term follow-up for metabolic risk.

Education

• Not specified in the available clinic profile materials.

Work experience

• Founder of YOUNIFY Clinic.

Clinical focus and techniques

At YOUNIFY Clinic, Noppachai Siranart focuses on endoscopy-based, minimally invasive options for weight regain and on evidence-informed planning for upper endoscopy in patients using GLP-1 medications.

• Advanced endoscopy.
• Endoscopic sleeve-in-sleeve revision performed through the mouth to suture or plicate the remaining sleeve, for selected patients with recurrent weight gain after sleeve gastrectomy.
• Upper endoscopy (esophagogastroduodenoscopy, EGD / gastroscopy) planning in patients taking GLP-1 receptor agonists, including semaglutide, liraglutide, dulaglutide, and tirzepatide.

Professional societies and certifications

• Thai Medical License.

Academic output

Siranart has contributed to patient-friendly research summaries on GLP-1 receptor agonists and upper endoscopy safety, including real-world data involving 629 patients undergoing upper endoscopy while using GLP-1 medications. He also contributed to a meta-analysis summary on GLP-1 receptor agonists and biopsy-confirmed MASH.

Courses and advanced training

• Not specified in the available clinic profile materials.

Awards and recognition

• Not specified in the available clinic profile materials.

For international patients, the clinic’s care pathway includes structured pre-endoscopy communication about GLP-1 medication timing and symptoms. Consultations are arranged through YOUNIFY Clinic, supporting coordinated decisions for upper endoscopy and weight-management planning.